CBD of Denver Inc. (OTCPK: CBDD)
Health Care · Pharmaceuticals · US
$0.00
+9900.00% today · -33.3% 1Y
CBD of Denver Inc. (OTCPK: CBDD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.11M and employs 2 people.
Over the last twelve months the share price has lost 33.3%, trading between 0.00 and 0.00.
Tweenvest scores CBD of Denver Inc. across four factors: value 100/100. Its strongest factor is value.
CBDD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.11M
- Revenue (TTM)
- $42.50K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -8.48
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 11.10B
- Employees
- 2
- Next earnings
- —
About CBD of Denver Inc.
CBD of Denver, Inc. engages in the cultivation, production, and distribution of cannabis flower and CBD products in Switzerland, Europe, and the US. Its brands include CBD Social Network, Black Peal CBD, and Rockflowr. The company was founded in 1993 and is headquartered in Centennial, CO.
- ISIN
- US12482B1070
- Listed since
- May 15, 1996
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.